Currently resident in JLabs San Diego, and previously (until 2014) doing business as CHOmics, Inc, Sinopia Biosciences is structured around development of a bioinformatics platform designed for drug discovery and drug re-purposing. Using proprietary machine learning, the effort is to identify therapeutics that reduce adverse drug reactions of life-changing medications. Utilizing advanced computational approaches to identify new solutions that improve drug efficacy and safety. Addressing a lead compound employed in Parkinson's Disease, a focus is on enabling doctors to identify pathways that are implicated in causing Parkinson's Disease. With an impressive Phase I to Phase II converstion record in NIH - their only SBIR source - the firm has no recorded instance of capital investment - a fairly rare situation in most firms inthis arena.
